Athira Pharma, Inc.

NasdaqGS:ATHA Voorraadrapport

Marktkapitalisatie: US$23.3m

Athira Pharma Beheer

Beheer criteriumcontroles 1/4

De CEO Athira Pharma is Mark Litton, benoemd in Oct2021, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.26M, bestaande uit 25.9% salaris en 74.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.47% van de aandelen van het bedrijf, ter waarde $ 108.49K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 3 jaar.

Belangrijke informatie

Mark Litton

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris25.9%
Dienstverband CEO3.1yrs
Eigendom CEO0.5%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur3yrs

Recente managementupdates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Analyse CEO-vergoeding

Hoe is Mark Litton's beloning veranderd ten opzichte van Athira Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$585k

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

Compensatie versus markt: De totale vergoeding ($USD 2.26M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.65K ).

Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mark Litton (56 yo)

3.1yrs

Tenure

US$2,261,564

Compensatie

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Litton
President3.1yrsUS$2.26m0.47%
$ 108.5k
Robert Renninger
VP of Financeless than a yeargeen gegevens0.20%
$ 46.4k
Kevin Church
Chief Scientific Officer1.8yrsUS$135.32k0.24%
$ 56.2k
Julie Rathbun
Head of Investor Relationsno datageen gegevensgeen gegevens
Mark Worthington
General Counsel3.4yrsUS$2.71m0.14%
$ 31.5k
Javier San Martin
Chief Medical Officerless than a yeargeen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATHA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Mark Litton
President3.1yrsUS$2.26m0.47%
$ 108.5k
John Fluke
Independent Director9.9yrsUS$95.89k0.38%
$ 87.8k
Grant Pickering
Independent Director2.8yrsUS$96.53k0.067%
$ 15.6k
Kelly Romano
Independent Chairwoman of the Board3.9yrsUS$124.68k0.21%
$ 48.9k
Joseph Edelman
Independent Director4.5yrsUS$92.77k0%
$ 0
Hans Moebius
Member of Scientific Advisory Board2.4yrsUS$1.29m0.24%
$ 55.4k
Marwan Sabbagh
Member of Scientific Advisory Board2.4yrsgeen gegevensgeen gegevens
Barbara Kosacz
Independent Director3.7yrsUS$102.39k0%
$ 0
Michael A. Panzara
Independent Director2.7yrsUS$89.36k0%
$ 0
James Johnson
Independent Director4.3yrsUS$106.87k0.013%
$ 3.0k
John Olichney
Member of Scientific Advisory Board2.4yrsgeen gegevensgeen gegevens
Anton Porsteinsson
Member of Scientific Advisory Board2.4yrsgeen gegevensgeen gegevens

3.0yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATHA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 3 jaar), wat duidt op een nieuw bestuur.